This is supported by the finding that in most NPM1-mutated AML patients, a small subset of early CD34+ hematopoietic precursors carrying NPM1 mutations/cytoplasmic NPM1 is usually present [11], suggesting a derivation from CD34+ hemopoietic stem cells, with the potential of multilineage differentiation. The gene discussed is NPM1; the disease is acute myeloid leukemia.